Work

Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial

Year: 2015

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: The Lancet Respiratory Medicine

DOI: 10.1016/s2213-2600(15)00201-5

Authors: Richard B Moss, Patrick A Flume, J Stuart Elborn, Jon Cooke, Steven M Rowe, Susanna A McColley, Ronald C Rubenstein, Mark Higgins

Institutions: Stanford Medicine, Stanford University, Medical University of South Carolina, Queen's University Belfast, Vertex Pharmaceuticals (United Kingdom), University of Alabama at Birmingham, Northwestern University, Children's Hospital of Philadelphia

Language: English

Topic: Cystic Fibrosis Research Advances

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Research Resources, National Center for Advancing Translational Sciences

Awards: Stanford Center for Clinical and Translational Education and Research (SCCTER)UL1, South Carolina Clinical & Translational Research Institute (SCTR), Institutional Clinical and Translational Science Award, General Clinical Research Center, Multidisciplinary Clinical and Translational Science (MCTS) Program (UL1), Institutional Clinical and Translational Science Award, UAB Center for Clinical and Translational Science (CCTS) UL1, UAB Center for Clinical and Translational Science (CCTS), UAB CF Research and Translation Core Center

OpenAlex ID: W2133435216

FWCI: 23.9

Cites: 41

Cited by: 229

Related to: 10